QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
QURE surges after the FDA said AMT-130 phase I/II data could support an accelerated approval filing for Huntington's disease.
Relaterede artikler
I går 23:03
Hogs Slipping Back Lower on ThursdayI går 22:05
Cotton Trading Mostly Lower on Thursday